Esbenshade Timothy A, Fox Gerard B, Krueger Kathleen M, Miller Thomas R, Kang Chae Hee, Denny Lynne I, Witte David G, Yao Betty B, Pan Liping, Wetter Jill, Marsh Kennan, Bennani Youssef L, Cowart Marlon D, Sullivan James P, Hancock Arthur A
Neuroscience Research, Abbott Laboratories, R4MN, AP9A, 100 Abbott Park Road, Abbott Park, IL 60064, USA.
J Pharmacol Exp Ther. 2005 Apr;313(1):165-75. doi: 10.1124/jpet.104.078303. Epub 2004 Dec 17.
Histamine H3 receptor antagonists are being developed to treat a variety of neurological and cognitive disorders that may be ameliorated by enhancement of central neurotransmitter release. Here, we present the in vitro pharmacological and in vivo pharmacokinetic profiles for the nonimidazole, benzofuran ligand ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile] and compare it with several previously described imidazole and nonimidazole H3 receptor antagonists. ABT-239 binds to recombinant human and rat H3 receptors with high affinity, with pK(i) values of 9.4 and 8.9, respectively, and is over 1000-fold selective versus human H1, H2, and H4 histamine receptors. ABT-239 is a potent H3 receptor antagonist at recombinant human and rat receptors, reversing agonist-induced changes in cAMP formation (pK(b) = 7.9 and 7.6, respectively), guanosine 5'-O-(3-[35S]thio) triphosphate ([35S]GTPgammaS) binding (pK(b) = 9.0 and 8.3, respectively), and calcium mobilization (human pK(b) = 7.9). ABT-239 also competitively reversed histamine-mediated inhibition of [3H]histamine release from rat brain cortical synaptosomes (pK(b) = 7.7) and agonist-induced inhibition of contractile responses in electric field stimulated guinea pig ileal segments (pA2 = 8.7). Additionally, ABT-239 is a potent inverse agonist, inhibiting constitutive [35S]GTPgammaS binding at both rat and human H3 receptors with respective pEC50 values of 8.9 and 8.2. ABT-239 demonstrates good pharmacokinetic characteristics in rat, dog, and monkey with t1/2 values ranging from 4 to 29 h, corresponding with clearance values and metabolic turnover in liver microsomes from these species, and good oral bioavailability ranging from 52 to 89%. Thus, ABT-239 is a selective, nonimidazole H3 receptor antagonist/inverse agonist with similar high potency in both human and rat and favorable drug-like properties.
组胺H3受体拮抗剂正处于研发阶段,用于治疗多种神经和认知障碍,这些障碍可能通过增强中枢神经递质释放而得到改善。在此,我们展示了非咪唑类苯并呋喃配体ABT - 239 [4-(2-{2-[(2R)-2-甲基吡咯烷基]乙基}-苯并呋喃-5-基)苄腈]的体外药理学和体内药代动力学特征,并将其与几种先前描述的咪唑类和非咪唑类H3受体拮抗剂进行比较。ABT - 239以高亲和力结合重组人源和大鼠H3受体,其pK(i)值分别为9.4和8.9,对人H1、H2和H4组胺受体的选择性超过1000倍。ABT - 239是重组人源和大鼠受体上的强效H3受体拮抗剂,可以逆转激动剂诱导的环磷酸腺苷(cAMP)形成变化(pK(b)分别为7.9和7.6)、鸟苷5'-O-(3-[35S]硫代)三磷酸([35S]GTPγS)结合变化(pK(b)分别为9.0和8.3)以及钙动员变化(人pK(b) = 7.9)。ABT - 239还能竞争性地逆转组胺介导的大鼠脑皮质突触体中[3H]组胺释放的抑制作用(pK(b) = 7.7)以及激动剂诱导的电场刺激豚鼠回肠段收缩反应的抑制作用(pA2 = 8.7)。此外,ABT - 239是一种强效反向激动剂,能抑制大鼠和人H3受体上组成型的[35S]GTPγS结合,其pEC50值分别为8.9和8.2。ABT - 239在大鼠、犬和猴体内表现出良好的药代动力学特征,半衰期值在4至29小时之间变化,这与这些物种肝脏微粒体中的清除率值和代谢周转率相对应,口服生物利用度良好,在52%至89%之间。因此,ABT - 239是一种选择性非咪唑类H3受体拮抗剂/反向激动剂,在人和大鼠中均具有相似的高效能以及良好的类药性质。